Theriva Biologics (TOVX) Cash from Operations (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Cash from Operations of 2456000.0 for Q1 2026, up 48.36% year-over-year from 1655433.11 in Q1 2025, and up 14.78% quarter-over-quarter from 2882000.0 in Q4 2025.
Theriva Biologics (TOVX) Cash from Operations (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Cash from Operations for 17 consecutive years, with 2456000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 48.36% year-over-year to 2456000.0; the TTM figure through Mar 2026 stood at 14369000.0 (up 14.53% YoY), while the FY2025 annual figure was 16669000.0, up 1.58% from the prior year.
- Cash from Operations rose to 2456000.0 in Q1 2026 per TOVX's latest filing, from 2882000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2456000.0 in Q1 2026 and bottomed at 6541000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 4361176.47 across 5 years, with a median of 4456000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 106.68% — and 2026, when it soared 48.36%.
- Theriva Biologics' Cash from Operations stood at 5368000.0 in 2022, then retreated by 21.85% to 6541000.0 in 2023, then gained by 28.28% to 4691000.0 in 2024, then jumped by 38.56% to 2882000.0 in 2025, then gained by 14.78% to 2456000.0 in 2026.
- Business Quant data shows TOVX's Cash from Operations at 2456000.0 in Q1 2026, 2882000.0 in Q4 2025, and 4319000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.09 Mn |
| Jun 30, 2026 | -3.09 Mn |
| Mar 31, 2026 | -2.46 Mn |
| Mar 31, 2026 | -2.46 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Sep 30, 2025 | -4.32 Mn |
| Sep 30, 2025 | -4.32 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Dec 31, 2024 | -4.69 Mn |
| Dec 31, 2024 | -4.69 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |